Robert Langer

During a proxy battle at Seer in 2026, the Radoff-JEC shareholder group claimed that Robert Langer could not be considered genuinely independent because of his longstanding relationship with co-founder Omid Farokhzad and criticised the board's oversight following the company's poor performance.

State of the evidence

Documented

Attribution

Direct responsibility

Moderna's spectacular rise during the pandemic made Robert Langer a billionaire through his stake in the company. This creation of private wealth became part of the American debate over how a vaccine developed with considerable public support could generate private fortunes and high prices after government purchasing ended.

State of the evidence

Documented

Attribution

Directly implicated

Moderna and the National Institutes of Health disagreed over the list of inventors on a key patent linked to the COVID-19 vaccine: the company had initially omitted three NIH scientists, although the agency considered that they had contributed to the invention. The affair fuelled criticism of private appropriation of work resulting from publicly funded collaboration.

State of the evidence

Documented

BIND Therapeutics, co-founded by Robert Langer to develop targeted nanoparticles against cancer, filed for Chapter 11 bankruptcy in 2016 following disappointing trials and financial difficulties. The collapse of a company once presented as one of nanomedicine's great promises fuelled criticism of the potential gap between spectacular academic innovations and clinical validation.

State of the evidence

Documented

Attribution

Direct responsibility

A Scientific American investigation into the underrepresentation of women on biotechnology scientific advisory boards cited several companies associated with Robert Langer whose advisory boards were exclusively male. Langer, a central figure in MIT's biotech ecosystem, became an unintended symbol of the debate over heavily male recruitment networks in scientific start-ups.

State of the evidence

Documented

During the contaminated heparin crisis, Robert Langer and Ram Sasisekharan participated in scientific work with the FDA while serving as directors or shareholders of Momenta Pharmaceuticals and advisers to Scientific Protein Laboratories. Nature Biotechnology emphasised that these links could create the appearance of a conflict of interest, given the analyses' significant regulatory and commercial implications.

State of the evidence

Documented

Attribution

Direct responsibility